RxDoctor Payments Data

Amy Daniel

Family · Cartersville, GANPI 1235478025

Payments from drug & device makers

$1,239in general payments, 2019–2025

Across 66 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Abbott$117
  • Pfizer$97
  • Sanofi-aventis U.S. LLC$92
  • Takeda Pharmaceuticals U.S.A., Inc.$81
  • Dexcom, Inc.$70
  • plus $491 from 17 others

What the payments were for

  • Food & beverage$1,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,239 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$19,451
Medicare patients
172
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$32,145
JardianceEmpagliflozin19$25,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,604
EliquisApixaban16$13,755
Tresiba Flextouch U-200Insulin Degludec12$9,475
Albuterol Sulfate HfaAlbuterol Sulfate69$2,163
Azelastine Hcl77$1,323
Celecoxib30$1,252
Diclofenac Sodium34$813
Gabapentin45$786
Levothyroxine Sodium84$783
Pantoprazole Sodium52$644
Bupropion XlBupropion Hcl13$610
Atorvastatin Calcium72$577
Fluticasone Propionate45$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$32,14525 claims
Boehringer IngelheimJardiance$13$25,16219 claims
PfizerEliquis$97$13,75516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Cartersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →